Skip to main content
European Commission logo print header

Better Bioprinting by Light-sheet Lithography

Project description

A novel top-down lithography approach to bioprinting will overcome current challenges

Tissue engineering has advanced significantly over the last decades. Bioprinting is currently the most promising method to produce functional engineered tissues. Conventional bottom-up, layer-by-layer printing is the norm yet there are significant challenges including viability and technical limitations to printing speed and spatial resolution. The EU-funded B-BRIGHTER project is developing a top-down lithography approach using ultra-high-speed digital light-sheet illumination to selectively photo-crosslink layers of cell-laden hydrogels mimicking specific tissues. The approach will quickly create functional 3D geometries with high spatial resolution. The team will develop a validated business case to support a path to market.

Objective

Bioprinting is considered the most promising method to produce functional engineered tissues with physiological properties. Successful tissue engineering will open research avenues for drug testing and therapeutic and will therefore raise much interest not only in the academia, but also pharma and clinical sectors. Current bioprinting methods are limited by combinations of insufficient speed, spatial resolution and cell viability. Since these technologies often suffer from poor spatial resolution and inability to control biomechanical properties, they fail to mimic the heterogeneous nature of native tissues. B-BRIGHTER aims to develop a novel bioprinting technology able to produce engineered tissues with high spatial resolution at high printing speed using an original top-down lithography approach. In contrast with current bottom up, layer-by-layer bioprinting methods, B-BRIGHTER aims at ultra high-speed digital light-sheet illumination strategy to selectively photo-crosslink cell-laden hydrogels mimicking specific tissues, in confined voxels and produce three-dimensional complex geometries. Previous advances from the BRIGHTER project will be extended by building complex bioengineered skin, cornea and gut tissue models, all of which represent pioneering examples for bioengineering, and its application for cell therapy, drug discovery and toxicology. Together with the work on patterning technology, bioink and application, a basis will be established for formulating a valid business case for a bioprinting product. The work on exploitation activities will ultimately result in a go-no go decision for the industrialisation of a bioprinting product and a commercial path forward. Ultimately, the goal of the B-BRIGHTER project is to provide a radically new bioprinting technology to boost the performance of various engineered tissues which in turn will promote improved healthcare opportunities, as well as business and employment advances in the European Union and beyond.

Funding Scheme

EIC - EIC
æ

Coordinator

MYCRONIC AB
Net EU contribution
€ 381 875,00
Address
Nytorpsvagen 9
183 03 Taby
Sweden

See on map

Region
Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Links
Other funding
€ 0,00

Participants (4)